Cipla is targeting “one sizeable respiratory inhalation launch in the US every year”, starting with albuterol in the firm’s next financial year ending March 2020, as part of ambitions to become a significant respiratory player in regulated markets.
Cipla is targeting “one sizeable respiratory inhalation launch in the US every year”, starting with albuterol in the firm’s next financial year ending March 2020, as part of ambitions to become a significant respiratory player in regulated markets.
Market entry for albuterol could be as early as the fourth quarter of Cipla’s 2019 financial year, but ultimately “we...
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
